Evidence map›Paper›PMID 33926024›Full record

ArticleJournal of clinical medicine2021

In Vivo Imaging of Thyroid Cancer with

Filippo Galli, Michela Varani, Chiara Lauri, Giuseppe Campagna, Lajos Balogh, Bruce D Weintraub, Mariusz W Szkudlinski, Armando Bartolazzi, Isabella Manni, Giulia Piaggio and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Filippo GalliNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.
Michela VaraniNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-7766-9031
Chiara LauriNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.
Giuseppe CampagnaNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-1884-9171
Lajos BaloghNational "Frederic Joliot Curie" Research Institute for Radiobiology and Radiohygiene, 1221 Budapest, Hungary.
Bruce D WeintraubTrophogen Inc., Rockville, MD 20850, USA.
Mariusz W SzkudlinskiTrophogen Inc., Rockville, MD 20850, USA.
Armando BartolazziPathology Research Laboratory, St. Andrea University Hospital, 00189 Rome, Italy.
Isabella ManniDepartment of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Giulia PiaggioDepartment of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0003-2114-1892
Alberto SignoreNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0001-8923-648X
Sapienza University of Rome · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITTrophogen (United States) · USCTO Andrea Alesini · ITFrédéric Joliot-Curie National Research Institute for Radiobiology and Radiohygiene · HU

Funding

Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.R44CA224376 · NCI · TROPHOGEN, INC. · PI SZKUDLINSKI, MARIUSZ WALDEMAR, WEINTRAUB, BRUCE DALE · 2018 to 2021
$1.8M
Associazione Italiana per la Ricerca sul Cancro 10369NCI NIH HHS R44 CA224376Sapienza Università di Roma RM11715C7D3AB597
6 · The paper itself

Abstract

Differentiated thyroid cancer (DTC) cells may lose NIS expression and iodine uptake, but usually express TSH receptors (TSHR). Therefore, the aim of our study was to compare two radiolabeled superagonist TSH analogues for DTC imaging. These analogues (namely TR1401 and TR1402) have a higher TSHR binding affinity than recombinant human TSH (Thyrogen

Indexed as

molecular imagingrhTSHthyroid cancerTR1402

Identifiers

PMID33926024
PMCPMC8123688
OpenAlexW3159421482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.